MedTrace Logo

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

NCT04355039 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-08-19

No results posted yet for this study

Summary

This is a prospective, single-center, open-label phase Ib study aimed at determining a recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will follow a 3 + 3 phase I dose-escalation design.

Conditions

  • Refractory Multiple Myeloma
  • Relapse Multiple Myeloma

Interventions

DRUG

INCB053914 65 mg BID

Dose level 1: 65 mg BID

DRUG

INCB053914 80 mg BID

Dose level 2: 80 mg BID

DRUG

Pomalidomide

4 mg Days 1-21

DRUG

Dexamethasone

40 mg Days 1, 8, 15 and 22

DRUG

INCB053914 50 mg bis in die (BID)

Dose level 0: 50 mg BID

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Binod Dhakal, MD · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-07-01
Completion
2024-07-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04355039 on ClinicalTrials.gov